Wells Fargo & Company Begins Coverage on Supernus Pharmaceuticals (NASDAQ:SUPN)

Wells Fargo & Company assumed coverage on shares of Supernus Pharmaceuticals (NASDAQ:SUPN – Get Free Report) in a note issued to investors on Friday, Marketbeat reports. The brokerage set an “overweight” rating and a $54.00 price target on the specialty pharmaceutical company’s stock. Wells Fargo & Company‘s price target points to a potential upside of 88.75% from the company’s current price.

Other equities analysts have also recently issued reports about the company. Weiss Ratings upgraded Supernus Pharmaceuticals from a “sell (d-)” rating to a “hold (c+)” rating in a report on Friday, November 13th. Jefferies Financial Group began coverage on Supernus Pharmaceuticals in a report on Wednesday, November 4th. They set a “strong-buy” rating for the company. Bank of America initiated coverage on Supernus Pharmaceuticals in a research report on Monday, November 9th. They issued a “buy” rating and a $47.00 price target for the company. Cantor Fitzgerald lifted their price target on Supernus Pharmaceuticals from $67.00 to $87.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 4th. Finally, Piper Sandler started coverage on Supernus Pharmaceuticals in a report on Wednesday, November 4th. They set an “overweight” rating and a $47.00 price objective on the stock. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $59.17.

Read Our Latest Analysis on Supernus Pharmaceuticals

Supernus Pharmaceuticals Trading Up 0.9%

NASDAQ:SUPN opened at $28.61 on Friday. The company has a 50-day moving average of $38.17 and a 200-day moving average of $45.81. The firm has a market cap of $3.38 billion, a price-to-earnings ratio of 7.99, a price-to-earnings-growth ratio of 0.58 and a beta of 0.84. Supernus Pharmaceuticals has a twelve month low of $25.92 and a twelve month high of $42.81.

Supernus Pharmaceuticals (NASDAQ:SUPN – Get Free Report) last released its earnings results on Thursday, October 29th. The specialty pharmaceutical company reported $0.35 EPS for the quarter, missing analysts’ consensus estimates of $0.49 by ($0.14). The business had revenue of $208.60 million during the quarter, compared to the consensus estimate of $217.56 million. Supernus Pharmaceuticals had a negative return on equity of 418.04% and a net margin of 32.75%. The firm’s revenue for the quarter was up 18.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.80) earnings per share. On average, research analysts forecast that Supernus Pharmaceuticals will post 3.80 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of SUPN. BlackRock Inc. purchased a new stake in Supernus Pharmaceuticals in the 2nd quarter worth about $434,871,000. Stephens Investment Management Group LLC grew its stake in Supernus Pharmaceuticals by 10.2% during the 3rd quarter. Stephens Investment Management Group LLC now owns 1,638,047 shares of the specialty pharmaceutical company’s stock valued at $58,724,000 after acquiring an additional 152,226 shares in the last quarter. GW&K Investment Management LLC increased its holdings in shares of Supernus Pharmaceuticals by 32.5% in the 3rd quarter. GW&K Investment Management LLC now owns 1,374,198 shares of the specialty pharmaceutical company’s stock valued at $49,265,000 after purchasing an additional 336,956 shares during the period. Goldman Sachs Group Inc. increased its holdings in shares of Supernus Pharmaceuticals by 36.1% in the 3rd quarter. Goldman Sachs Group Inc. now owns 1,115,001 shares of the specialty pharmaceutical company’s stock valued at $39,973,000 after purchasing an additional 295,569 shares during the period. Finally, Bank of America Corp DE increased its holdings in shares of Supernus Pharmaceuticals by 37.2% in the 1st quarter. Bank of America Corp DE now owns 714,226 shares of the specialty pharmaceutical company’s stock valued at $36,918,000 after purchasing an additional 193,479 shares during the period.

About Supernus Pharmaceuticals

(Get Free Report)

Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing treatments for central nervous system disorders. Its work spans neurology and psychiatry, including therapies for epilepsy, attention-deficit/hyperactivity disorder (ADHD), and Parkinson’s disease. The company’s marketed products include Qelbree for ADHD; Oxtellar XR and Trokendi XR for epilepsy; and medicines for Parkinson’s disease, including Apokyn, Xadago, and Ongentys. Its portfolio also includes Gocovri, which is used to treat certain movement complications associated with Parkinson’s disease.

Further Reading

Analyst Recommendations for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.